What 6 Analyst Ratings Have To Say About Regenxbio
Portfolio Pulse from Benzinga Insights
Regenxbio (NASDAQ:RGNX) has received mixed analyst ratings in the last quarter, with 1 bullish, 3 somewhat bullish, and 2 indifferent ratings. The average 12-month price target for the stock is $37.0, a decrease of 13.95% from the previous average of $43.00.
July 12, 2023 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mixed analyst ratings and a decreased price target could lead to uncertainty among investors, potentially impacting Regenxbio's stock price.
Analyst ratings can significantly influence investor sentiment. The mixed ratings for Regenxbio, coupled with a decreased price target, could lead to uncertainty among investors, potentially causing fluctuations in the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100